PIK3CA E109del

c.325_327delGAA NM_006218.3 PI3K-AKT indel, gain of function

Cancer hotspot Recurrent inframe deletion. COSMIC COSV55874554

Population · gnomAD — gnomAD v4

ClinVar Not in ClinVar no exact-match submission

Protein region inter-domain region Residue 109 of PIK3CA. UniProt P42336

Position in PIK3CA 15 catalogued

Reported in LM

ISSVA subset	Allele fraction	Sources
LM	n.r. (LEC line; Sanger, not quantified)	PMID29985963

Pathway and targeted therapy

Driver of the PI3K-AKT pathway. Repurposed drugs already used in the clinic for this pathway: alpelisib (PI3Kα inhibitor), sirolimus (mTOR inhibitor).

Open and recent trials (3 in vascular / lymphatic anomalies for alpelisib)

Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation. RECRUITING NCT05948943 · PHASE2, PHASE3
A Trial of Targeted Therapies for Patients With Slow-Flow or Fast-Flow Vascular Malformations RECRUITING NCT05983159 · PHASE2
24VA022; VATCH Alpelisib for TIE2/PIK3CA Pathway VAs ACTIVE NOT RECRUITING NCT07543822 · PHASE2

Primary sources (1)

PIK3CA mutations are specifically localized to lymphatic endothelial cells of lymphatic malformations.
Blesinger H, Kaulfuß S, Aung T, Schwoch S, Prantl L, Rößler J, Wilting J, Becker J. · PLoS One · 2018

Mentioned in 6 publications indexed by Europe PMC.

Cross-references

COSMIC COSV55874554 gnomAD · PIK3CA ClinVar · E109del OncoKB cBioPortal · PIK3CA UniProt · PIK3CA AlphaFold · PIK3CA